source
- Oak Hill Bio to go public via SPAC merger, securing $175 million for Angelman syndrome programOak Hill Bio announced it will become a publicly traded company through a merger with the special purpose acquisition company Research Alliance Corporation III. The transaction will provide $75 mi…
- Webinar Explores AI-Driven Intelligence Engine for Optimizing Antibody, ADC and Peptide CandidatesDrug discovery teams are grappling with an ever‑growing volume of data, and converting that data into actionable insight remains a key hurdle. In a recent BioSpace webinar, Patsnap’s Ben Coverdale…